51. Biomarkers in Atrial Fibrillation
- Author
-
Stanley Nattel, Prashanthan Sanders, Jean Jacques Noubiap, and Dennis H. Lau
- Subjects
biology ,business.industry ,Clinical events ,Atrial fibrillation ,030204 cardiovascular system & hematology ,medicine.disease ,Bioinformatics ,Troponin ,Pathophysiology ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,biology.protein ,Medicine ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Stroke ,Clinical risk factor ,Major bleeding - Abstract
Biomarkers derived from the key components of the pathophysiology of atrial fibrillation (AF) and its complications have the potential to play an important role in earlier characterization of AF phenotype and in risk prediction of adverse clinical events, which may translate into improved management strategies. C-reactive protein, natriuretic peptides, cardiac troponins, growth differentiation factor-15, and fibroblast growth factor-23 have been shown to be the most promising biomarkers in AF. Some biomarkers have already been included in clinical risk scores to predict postoperative AF, thromboembolism, major bleeding, and death. Considerably more work is needed to bring these novel biomarkers into routine clinical management of patients with AF.
- Published
- 2021